查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1916896

人類肺模型市場：按模型類型、技術、應用和最終用戶分類 - 全球預測（2026-2032 年）

Human Lung Models Market by Model Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，人類肺模型市場價值將達到 3.3232 億美元，到 2026 年將成長至 3.6141 億美元，到 2032 年將達到 5.6443 億美元，年複合成長率為 7.86%。

關鍵市場統計數據
基準年 2025 3.3232億美元
預計年份：2026年 3.6141億美元
預測年份 2032 5.6443億美元
複合年成長率 (%) 7.86%

簡潔地介紹人類肺模型領域的最新進展，將技術進步、轉化研究重點和決策者的策略要務連結起來。

生物學、工程學和計算科學的融合催生了人類肺部模型，這些模型正在重塑呼吸系統疾病的研究方式、治療方法的開發以及安全性的評估。組織工程、類器官培養、微流體和高解析度成像技術的進步，共同建構了能夠以前所未有的精度重現肺部結構、力學和細胞複雜性的模型。同時，In Silico方法和整合計算框架透過將分子數據與組織層面的行為聯繫起來，增強了預測能力並提高了轉換應用價值。

技術變革、共同研究模式和檢驗重點的轉變正在加速肺部系統的轉化應用和產業化應用。

隨著微工程、3D培養系統和計算模擬技術的突破，以及監管環境和商業性壓力的不斷變化，人類肺模型的模式正在迅速改變。技術的成熟使得長期培養穩定性得以實現，細胞類型複雜性得以提高，血管和免疫成分得以整合，從而更真實地再現疾病進程。同時，生物列印和先進的支架製造技術能夠以更高的通量建構解剖學相關的模型，從而可以進行跨不同疾病和治療方法的比較研究。

2025年關稅主導的供應鏈變化如何重塑了肺部模型研究生態系統的籌資策略、供應商網路和營運韌性

貿易和關稅政策的變化會對維持複雜肺部模型系統所必需的科學設備、專用耗材和試劑的供應鏈產生重大影響。增加實驗室設備、聚合物支架、生物列印材料和試劑進口成本的關稅會導致實驗週期延長和單次實驗成本上升，尤其對於資源密集的3D培養和類器官維護而言更是如此。採購延誤和成本壓力往往會對缺乏多元化供應商網路和充足庫存的小規模學術實驗室和新興生物技術公司造成不成比例的影響。

將建模方法、底層技術、轉換應用和最終用戶優先順序與策略決策流程連結起來的綜合細分分析

理解模型細分的細微差別對於確定投資優先順序和設計轉換路徑至關重要。在考慮模型類型時，必須認知到每種模型的作用：用於急性轉化測試的離體模型、用於假設生成和參數探索的In Silico平台、用於機制研究和篩檢活動的體外系統、用於捕捉整個生物體環境的體內模型，以及能夠重現患者來源複雜性的類器官培養物。在體外方法中，2D細胞株仍適用於高通量檢測，而3D培養物則能提供更接近組織生理的結構和細胞間相互作用。原代細胞培養物具有人類特異性生物學特性，但需要謹慎選擇供體來源並品管。3D培養物本身也在不斷發展，例如基於支架的結構（可提供可控的機械性能）和無支架聚集體（強調自組織和細胞行為）。

美洲、歐洲、中東和非洲以及亞太地區各區域策略的差異和互補優勢將影響發展和商業化路徑。

區域趨勢正在影響人類肺模型技術的開發、檢驗和商業化方式。美洲地區聚集了大量的學術醫療中心、創業投資的生物技術公司和醫療器材製造商，這得益於強大的臨床試驗生態系統，該系統能夠促進臨床檢驗，從而加速從原型到商業化的轉化。這種環境強調與國家監管機構的協調一致、擴充性，並鼓勵轉化研究實驗室和商業團隊之間的合作，以加速產品開發。

概述促進平台成熟度、檢驗和商業性擴充性的組織能力和協作角色，這些能力和角色將加速整個生態系統的發展。

關鍵企業和機構參與者正在推動平台創新，促進轉化研究流程，並塑造人類肺部模型技術的商業化路徑。設備製造商和專用耗材供應商在定義平台功能以及透過標準化試劑和檢驗的硬體來支援可重複性方面發揮關鍵作用。專注於類器官衍生和幹細胞技術的生物技術公司正在擴展與疾病相關的患者來源模型的範圍，而專注於生物列印硬體和微流體裝置工程的供應商則致力於實現結構和動態的精確性。

領導者可以採取切實可行的營運和策略措施，以提高平台互通性、檢驗嚴謹性、供應鏈彈性和與轉換研究的一致性。

希望利用人類肺模型最新進展的領導者應採取一系列切實可行的策略，以平衡科學可信度和商業性可行性。首先，應優先考慮平台模組化和互通性，從而保護前期前期投資，使新技術無需大規模檢驗即可整合。其次，應投資嚴格、標準化的檢驗通訊協定，強調生物學可重複性和實驗室間可比性。此類通訊協定可降低監管談判中的風險，並增強夥伴關係中的價值主張。此外，各組織也應實現供應商關係多元化，制定庫存策略以降低供應鏈中斷的風險，並考慮區域採購和生產，以減少關稅波動和物流延遲的影響。

結合文獻綜述、專家訪談和生態系統分析的嚴謹的多源調查方法，能夠得出可靠的研究結果並減少解釋偏差。

本分析的調查方法整合了多方面的證據，旨在對人體肺模型提供平衡客觀的觀點。此方法首先對原始文獻、技術白皮書、監管指導文件和同行評審的研究文章進行系統性回顧，並以實證研究結果佐證技術說明和檢驗實踐。隨後，研究人員與包括學術研究人員、轉化科學家、設備工程師和商業領袖在內的相關領域專家進行了深入訪談和結構化討論，以揭示實際挑戰、應用促進因素和新興的夥伴關係模式。

最終成果是將技術進步、供應鏈經驗教訓和策略重點相結合，重點是檢驗、互通性和轉換影響。

總而言之，人類肺模型正從專門的研究工具轉變為轉化醫學流程中不可或缺的組成部分，為藥物發現、精準醫療和安全性評估提供資訊。 3D培養、生物列印、微流體、成像和計算建模等領域的技術進步正在融合，從而提高模型的生理相關性和數據豐富度。 2025年關稅導致的供應鏈中斷凸顯了在地採購、多元化供應商網路和業務永續營運的重要性，促使各組織重新思考其採購和夥伴關係策略。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依模型類型分類的人類肺模型市場

  • Ex Vivo
  • In Silico
  • 體外
    • 2D細胞株
    • 3D文化
      • 鷹架底座
      • 無支架
    • 原代細胞培養
  • In vivo
  • 類器官

9. 按技術分類的人類肺模型市場

  • 生物列印
  • 計算建模
  • 影像
    • 電腦斷層掃描
    • 磁振造影
    • 顯微鏡
  • 微流體技術

第10章 按應用分類的人類肺模型市場

  • 疾病模型
    • 癌症
    • COPD
    • 纖維化
    • 呼吸道感染疾病
  • 藥物發現
  • 精準醫療
  • 毒性測試

第11章 以最終使用者分類的人類肺模型市場

  • 學術和研究機構
  • CRO（受託研究機構）
  • 醫院和診所
  • 製藥和生物技術公司

第12章 區域性人類肺部模型市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 人類肺模型市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國人肺模型市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章美國人類肺部模型市場

第16章：中國人體肺模型市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AlveoliX Sarl
  • CN Bio Innovations Limited
  • Emulate, Inc.
  • Epithelix Sarl
  • Hurel Corporation
  • InSphero AG
  • MatTek Corporation
  • MIMETAS BV
  • Nortis, Inc.
  • TissUse GmbH
Product Code: MRR-AE420CB153DB

The Human Lung Models Market was valued at USD 332.32 million in 2025 and is projected to grow to USD 361.41 million in 2026, with a CAGR of 7.86%, reaching USD 564.43 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 332.32 million
Estimated Year [2026] USD 361.41 million
Forecast Year [2032] USD 564.43 million
CAGR (%) 7.86%

A concise orientation to the evolving field of human lung models that connects technological advances, translational priorities, and strategic imperatives for decision-makers

Human lung models represent a convergence of biology, engineering, and computational science that is reshaping how respiratory disease is studied, how therapeutics are developed, and how safety is assessed. Advances in tissue engineering, organoid culture, microfluidics, and high-resolution imaging have collectively enabled models that recapitulate structural, mechanical, and cellular complexity of the lung at unprecedented fidelity. In parallel, in silico approaches and integrated computational frameworks are enhancing predictive capability by connecting molecular data to tissue-level behavior, thereby improving translational relevance.

This summary synthesizes key developments across model modalities, technologies, applications, end users, and geographies to provide a concise, actionable perspective for senior decision-makers. It highlights the forces driving adoption, the technical and regulatory barriers that persist, and the strategic moves organizations are executing to capture translational value. By focusing on reproducibility, scalability, and clinical relevance, stakeholders can better align research investments with opportunities in drug discovery, precision medicine, and safety assessment. Moreover, the evolving interplay between experimental and computational models is creating hybrid workflows that accelerate hypothesis testing and reduce dependence on traditional animal models. Consequently, leaders in academia, industry, and healthcare are repositioning capabilities to harness these complementary strengths and to de-risk late-stage development.

Transformative shifts in technologies, collaborative models, and validation priorities that are fast-tracking translational relevance and industrial adoption of lung systems

The landscape for human lung models is shifting rapidly as breakthroughs in microengineering, three-dimensional culture systems, and computational simulation converge with changing regulatory expectations and commercial pressures. Technological maturation is enabling long-term culture stability, improved cell-type complexity, and the integration of vasculature and immune components, which in turn allow for more faithful recapitulation of disease processes. At the same time, bioprinting and advanced scaffold fabrication techniques are making it feasible to create anatomically relevant constructs at increasing throughput, enabling comparative studies across conditions and therapeutic modalities.

Concurrently, computational modeling and machine learning are enhancing interpretation of multimodal data, enabling more robust in silico-to-in vitro bridging studies. Imaging modalities have progressed to deliver dynamic, longitudinal readouts that reduce reliance on endpoint-only assays. These developments are prompting a shift from isolated proof-of-concept demonstrations toward standardized, modular platforms that prioritize compatibility with regulatory and industrial workflows. As a result, cross-sector collaborations between instrument providers, reagent manufacturers, contract research organizations, and clinical investigators are becoming the norm. This trend emphasizes platform interoperability, data standards, and validation frameworks that support evidence generation for both efficacy and safety, which ultimately accelerates translation from bench to bedside.

How tariff-driven supply chain shifts in 2025 reshaped procurement strategies, supplier networks, and operational resilience across lung model research ecosystems

Policy changes in trade and tariffs can materially affect supply chains for scientific instruments, specialized consumables, and the reagents essential to maintaining complex lung model systems. Tariffs that increase import costs on laboratory equipment, polymeric scaffolds, bioprinting materials, and reagents can extend procurement timelines and elevate per-experiment costs, particularly for resource-intensive 3D cultures and organoid maintenance. Procurement delays and cost pressures tend to disproportionately impact smaller academic labs and emerging biotechnology firms that lack diversified supplier networks or extensive inventories.

In the context of the United States tariffs enacted in 2025, organizations responded by reshaping sourcing strategies, rationalizing inventory holdings, and accelerating qualification of alternate suppliers. This pivot created immediate demand for domestic manufacturing partners and for regional distributors that could provide rapid fulfillment and technical support. As a result, some service providers and contract research organizations restructured operational footprints to reduce cross-border exposure, while instrument vendors increased localized service hubs. Over time, these adjustments altered procurement patterns, with larger institutions leveraging their purchasing power to negotiate bundled service agreements and smaller teams seeking collaborations that provide shared access to capital-intensive platforms. Importantly, the cumulative effect emphasized supply-chain resilience and prompted renewed attention to backward compatibility of consumables with legacy instruments to avoid disruptive requalification efforts.

Integrated segmentation insights that map model modalities, enabling technologies, translational applications, and end-user priorities to strategic decision pathways

A nuanced understanding of segmentation is essential to prioritize investments and design translational pathways. When examining model types, it is important to recognize the distinct roles of ex vivo preparations for acute translational testing, in silico platforms for hypothesis generation and parameter exploration, in vitro systems for mechanistic and screening activities, in vivo models for whole-organism context, and organoid cultures for patient-derived complexity. Within in vitro approaches, two-dimensional cell lines remain valuable for high-throughput assays, whereas three-dimensional cultures provide architecture and cell-cell interactions that better mimic tissue physiology; primary cell cultures offer human-specific biology but require careful donor sourcing and quality control. Three-dimensional cultures themselves split into scaffold-based constructs that afford controlled mechanical properties and scaffold-free assemblies that emphasize self-organization and cellular behavior.

From a technology standpoint, bioprinting enables spatial patterning and scale, computational modeling offers predictive scaling and virtual experimentation, imaging provides structural and functional readouts, and microfluidics recreates flow and mechanical cues. Imaging modalities are not interchangeable; computed tomography offers macroscopic structural resolution in ex vivo contexts, magnetic resonance imaging supplies soft-tissue contrasts and functional mapping, and microscopy delivers cellular and subcellular insights. Application-driven segmentation clarifies pathway choices: disease modeling spans cancer, chronic obstructive pulmonary disease, fibrotic processes, and respiratory infections, each demanding different cell compositions and readouts. Drug discovery workflows prioritize throughput and assay robustness, precision medicine emphasizes patient-specific models and biomarker linkage, and toxicity testing requires standardized endpoints and regulatory alignment. Finally, the end-user landscape ranges from academic and research institutes focused on mechanism and methodology development, through contract research organizations that translate platforms into service offerings, to hospitals and clinics seeking clinically relevant diagnostics and therapeutic validation, and pharmaceutical and biotechnology companies that integrate models into preclinical decision making. Understanding how these segments intersect guides decisions on platform design, validation pathways, and partnership models.

Regional strategic contrasts and complementary strengths across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence development and commercialization pathways

Regional dynamics are shaping how human lung model innovations are developed, validated, and commercialized. In the Americas, a dense concentration of academic medical centers, venture-backed biotechnology firms, and instrument manufacturers fosters rapid prototype-to-commercial transitions, supported by robust clinical trial ecosystems that facilitate clinical validation. This environment prioritizes scalability and regulatory alignment with domestic authorities and incentivizes partnerships between translational research labs and commercial teams to accelerate productization.

In Europe, Middle East & Africa, the landscape is characterized by strong public research funding, collaborative consortia, and a cautious regulatory framework that emphasizes human-relevant models and reduction of animal testing. Cross-border initiatives and harmonized standards are driving adoption of interoperable platforms and shared validation studies, while regional manufacturing hubs are emerging to support localized supply chains. In Asia-Pacific, large-scale investments in biotech manufacturing capacity, rapid clinical development timelines, and an expanding base of CROs have created an environment that emphasizes cost-effectiveness and rapid iteration. Many organizations in the region are investing heavily in automation and high-throughput platforms to support large-scale screening and regional clinical partnerships. Collectively, these regional contrasts create complementary strengths and underscore the importance of geographically informed commercialization and partnership strategies that account for regulatory nuance, supply-chain realities, and local clinical priorities.

Profiles of the organizational capabilities and collaborative roles that are accelerating platform maturity, validation, and commercial scalability across the ecosystem

Key corporate and institutional actors are driving platform innovation, enabling translational pipelines, and shaping commercial pathways for human lung model technologies. Instrument manufacturers and specialty consumable suppliers are crucial in defining platform capabilities and supporting reproducibility through standardized reagents and validated hardware. Biotechnology companies focused on organoid derivation and stem cell technologies are expanding the range of disease-relevant, patient-derived models, while engineering-focused vendors of bioprinting hardware and microfluidic devices are enabling architectural and biomechanical fidelity.

Service providers and contract research organizations are evolving from simple assay vendors into strategic partners that offer integrated workflows spanning model development, assay validation, and regulatory documentation. Imaging and analytics firms are enhancing the ability to extract actionable readouts from complex, multimodal data, creating value through software platforms and analytical pipelines. Academic centers and translational research institutes continue to contribute foundational methods and early validation studies, often in collaboration with industry partners to accelerate commercial deployment. Collectively, these players are coalescing around validation frameworks, data standards, and interoperability practices that reduce friction for adoption and support broader reproducibility across labs and organizations.

Actionable operational and strategic moves that leaders can deploy to improve platform interoperability, validation rigor, supply resilience, and translational alignment

Leaders seeking to capitalize on advances in human lung models should adopt a set of pragmatic, tactical actions to align scientific credibility with commercial viability. First, prioritize platform modularity and interoperability so that new technologies can be integrated without extensive requalification, thereby protecting earlier investments. Next, invest in rigorous, standardized validation protocols that emphasize biological reproducibility and cross-laboratory comparability; such protocols de-risk regulatory conversations and strengthen value claims in partnerships. Organizations should also diversify supplier relationships and build inventory strategies to mitigate supply-chain shocks, while exploring regional sourcing and manufacturing to reduce exposure to tariff volatility and logistics delays.

Furthermore, foster translational collaborations that pair technical developers with clinical and regulatory experts early in the product lifecycle, enabling endpoint alignment and smoother pathways to clinical relevance. Embrace hybrid workflows that combine in vitro, organoid, in silico, and imaging modalities to generate richer evidence packages that support both efficacy and safety assessments. Lastly, develop clear commercialization strategies that delineate productized platforms, service offerings, and data licensing models, and ensure these strategies are informed by regional regulatory nuance and end-user procurement practices. By executing these actions, organizations can accelerate adoption, reduce technical risk, and capture greater translational value from their investments.

A rigorous, multi-source research methodology combining literature synthesis, expert interviews, and ecosystem analysis to derive robust insights and reduce interpretive bias

The research methodology underpinning this analysis integrates multiple evidence streams to provide a balanced and objective perspective on human lung models. The approach began with a systematic review of primary literature, technical white papers, regulatory guidance documents, and peer-reviewed studies to ground technological descriptions and validation practices in empirical findings. Next, in-depth interviews and structured discussions with domain experts-spanning academic investigators, translational scientists, instrument engineers, and commercial leaders-were conducted to surface practical challenges, adoption drivers, and emergent partnership models.

Complementing qualitative inputs, technology and workflow analyses were performed to map capability overlaps, identify integration points across modalities, and assess operational dependencies such as consumable lifecycles and maintenance requirements. Regional ecosystem assessments were informed by public funding announcements, patent activity, and observed shifts in corporate strategy to characterize geographic strengths and supply-chain considerations. Throughout, triangulation across data sources was used to corroborate insights and to mitigate bias. Where appropriate, sensitivity checks and validation interviews were employed to refine interpretations and ensure the conclusions reflect consensus perspectives from multiple stakeholder groups.

A distilled synthesis of technological progress, supply-chain lessons, and strategic priorities that emphasizes validation, interoperability, and translational impact

In summary, human lung models are transitioning from specialized research tools to integral components of translational pipelines that inform drug discovery, precision medicine, and safety assessment. Technological advances in three-dimensional culture, bioprinting, microfluidics, imaging, and computational modeling are collectively enhancing physiological relevance and data richness. Tariff-induced supply-chain disruptions in 2025 emphasized the need for localized sourcing, diversified supplier networks, and operational resilience, prompting organizations to rethink procurement and partnership strategies.

Strategic segmentation across model type, technology, application, and end user reveals distinct priorities and interoperability requirements that should guide investment and collaboration decisions. Region-specific strengths create opportunities for complementary partnerships that bridge prototype development with scale-up and clinical validation. Ultimately, organizations that prioritize standardized validation, cross-platform interoperability, and early clinical alignment will be best positioned to translate technical advances into sustainable clinical and commercial outcomes. This synthesis is intended to support executive decision-making and to catalyze targeted actions that accelerate the real-world impact of human lung model innovations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Lung Models Market, by Model Type

  • 8.1. Ex Vivo
  • 8.2. In Silico
  • 8.3. In Vitro
    • 8.3.1. 2D Cell Lines
    • 8.3.2. 3D Cultures
      • 8.3.2.1. Scaffold-Based
      • 8.3.2.2. Scaffold-Free
    • 8.3.3. Primary Cell Cultures
  • 8.4. In Vivo
  • 8.5. Organoid

9. Human Lung Models Market, by Technology

  • 9.1. Bioprinting
  • 9.2. Computational Modeling
  • 9.3. Imaging
    • 9.3.1. Computed Tomography
    • 9.3.2. Magnetic Resonance Imaging
    • 9.3.3. Microscopy
  • 9.4. Microfluidics

10. Human Lung Models Market, by Application

  • 10.1. Disease Modeling
    • 10.1.1. Cancer
    • 10.1.2. COPD
    • 10.1.3. Fibrosis
    • 10.1.4. Respiratory Infections
  • 10.2. Drug Discovery
  • 10.3. Precision Medicine
  • 10.4. Toxicity Testing

11. Human Lung Models Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Hospitals & Clinics
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Human Lung Models Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Human Lung Models Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Human Lung Models Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Human Lung Models Market

16. China Human Lung Models Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AlveoliX Sarl
  • 17.6. CN Bio Innovations Limited
  • 17.7. Emulate, Inc.
  • 17.8. Epithelix Sarl
  • 17.9. Hurel Corporation
  • 17.10. InSphero AG
  • 17.11. MatTek Corporation
  • 17.12. MIMETAS B.V.
  • 17.13. Nortis, Inc.
  • 17.14. TissUse GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN LUNG MODELS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN LUNG MODELS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HUMAN LUNG MODELS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HUMAN LUNG MODELS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HUMAN LUNG MODELS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN LUNG MODELS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY EX VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IN SILICO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IN SILICO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IN SILICO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY 2D CELL LINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY 2D CELL LINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY 2D CELL LINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY SCAFFOLD-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY SCAFFOLD-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY SCAFFOLD-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY SCAFFOLD-FREE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY SCAFFOLD-FREE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY SCAFFOLD-FREE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY PRIMARY CELL CULTURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY PRIMARY CELL CULTURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY PRIMARY CELL CULTURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IN VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY ORGANOID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY ORGANOID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY ORGANOID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY BIOPRINTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY BIOPRINTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY BIOPRINTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY COMPUTATIONAL MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY COMPUTATIONAL MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY COMPUTATIONAL MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY MICROFLUIDICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY MICROFLUIDICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY COPD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY COPD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY COPD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY FIBROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY FIBROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY FIBROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY PRECISION MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY PRECISION MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY PRECISION MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY TOXICITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY TOXICITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY TOXICITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS HUMAN LUNG MODELS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA HUMAN LUNG MODELS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. GCC HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GCC HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 183. GCC HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 184. GCC HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 186. GCC HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. GCC HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 188. GCC HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. G7 HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. G7 HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 210. G7 HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 211. G7 HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. G7 HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 213. G7 HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. G7 HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 215. G7 HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. NATO HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. NATO HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 219. NATO HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 220. NATO HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. NATO HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 222. NATO HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. NATO HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 224. NATO HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES HUMAN LUNG MODELS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA HUMAN LUNG MODELS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)